{"contentid": 488753, "importid": NaN, "name": "Full results presented on PharmaMar\u00e2\u0080\u0099s Aplidin in COVID-19 requiring hospitalization", "introduction": "Spanish biopharma PharmaMar has announced the final results of its APLICOV-PC trial with Aplidin\u00c2\u00a0(plitidepsin) for the treatment of adults with COVID-19 requiring hospitalization, which met the primary safety endpoint and showed clinical efficacy.", "content": "<p>Spanish biopharma PharmaMar (MSE: PHM) has announced the final results of its APLICOV-PC trial with Aplidin&nbsp;(plitidepsin) for the treatment of adults with COVID-19 requiring hospitalization, which met the primary safety endpoint and showed clinical efficacy.</p>\n<p>In view of the start of the Phase III NEPTUNO trial, the company has decided to share this data, which demonstrates the therapeutic potential of this drug with the entire scientific and medical communities, along with patients.</p>\n<p><span class=\"pullQuote\">\"With the opening of recruitment for the NEPTUNO trial and a head-to-head comparator group, we will be able to know more precisely what the clinical role and efficacy of plitidepsin in COVID-19 is\"</span>The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.</p>\n<p>Of the 45 patients treated in the trial, 86.7% had moderate or severe disease. 91% had pneumonia, with 71% having bilateral pneumonia.</p>\n<p>In the results obtained in this study, the data observed in 23 patients with moderate disease stand out, 74% were discharged from hospital in the first week of treatment.</p>\n<p>Those who received the 2.5mg dose were most likely to be discharged during the first week of hospitalization.</p>\n<p>In this same group of patients, it has been observed that the higher the dose of plitidepsin, the higher the lymphocyte count over time, an indicator of improvement of the immune system.</p>\n<p>Likewise, a parallelism is observed between the decrease in viral load, clinical improvement and the fall in inflammation parameters, such as C-reactive protein.</p>\n<p>This suggests that, in addition to its antiviral effect, plitidepsin could be exerting anti-inflammatory effects, favoring the immune response against SARS-CoV-2.</p>\n<p>This publication also reaffirms the initial hypotheses on the transversality of plitidepsin against other strains or variants of coronavirus, since it acts by blocking the eEF1A protein, present in human cells, which is used by different types of coronavirus to reproduce and infect other cells.</p>\n<p>The data obtained in this study have led PharmaMar to launch the new Phase III NEPTUNO study, which will determine the efficacy of plitidepsin for the treatment of hospitalized patients with moderate COVID-19 infection.</p>\n<p>Pablo Guisado Vasco, consultant internal medicine at Hospital Universitario Quir&oacute;nsalud Madrid, said: \"We still need effective drugs against COVID-19. Plitidepsin is a very promising compound with a solid pre-clinical development. It has completed the Phase I/II study with good safety and early clinical data demonstrating an adequate efficacy in moderate COVID-19 pneumonia.</p>\n<p>\"In the coming weeks, with the opening of recruitment for the NEPTUNO trial and a head-to-head comparator group, we will be able to know more precisely what the clinical role and efficacy of plitidepsin in COVID-19 is.\"</p>", "date": "2021-05-26 17:43:00", "meta_title": NaN, "meta_keywords": "plitidepsin, COVID-, trial, clinical, efficacy, results, hospitalization, patients, requiring, treatment, moderate, study, APLICOV-PC, NEPTUNO, PharmaMar", "meta_description": "Spanish biopharma PharmaMar has announced the final results of its APLICOV-PC trial with Aplidin\u00c2\u00a0(plitidepsin) for the treatment of adults with COVID-19 requiri", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-26 17:41:50", "updated": "2021-05-26 19:53:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/full-results-presented-on-pharmamar-s-aplidin-in-covid-19-requiring-hospitalization", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "pharmamarbig.jpg", "image2id": "pharmamarsmall.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Spain", "company_tag": "PharmaMar", "drug_tag": "Aplidin, plitidepsin", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-26 17:43:00"}